Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2017-06-09Clinical Trial Update: Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating carbon monoxide therapy for severe pulmonary arterial hypertension was withdrawn.
-
CLINICAL_TRIALS research · 2017-06-09Clinical Trial Update: Registry for Pulmonary Hypertension in China
An update on the Registry for Pulmonary Hypertension in China; the trial status is currently UNKNOWN.
-
CLINICAL_TRIALS trial_result · 2017-06-08Clinical Trial Update: Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension [Phase 1, Phase 2]
A pilot Phase 1/2 study evaluating the safety and efficacy of carvedilol in pulmonary arterial hypertension, with results posted in June 201…
-
FDA approval · 2017-06-07FDA Approved: ORENITRAM — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for ORENITRAM (treprostinil) from United Therapeutics Corporation.
-
EMA guidance · 2017-06-06Workshop: addressing unmet needs of children with pulmonary arterial hypertension
EMA workshop focused on identifying and addressing unmet medical needs for children with pulmonary arterial hypertension to inform future re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
This completed study evaluated real-world treatment patterns in patients with pulmonary arterial hypertension or chronic thromboembolic pulm…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH) [Phase 4]
Phase 4 open-label study assessing safety and efficacy of ambrisentan in exercise-induced pulmonary arterial hypertension completed with pos…
-
CLINICAL_TRIALS withdrawal · 2017-05-09Clinical Trial Update: An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension [Phase 4]
An open-label extension study evaluating the safety of continued subcutaneous Remodulin (treprostinil) in pulmonary arterial hypertension ha…
-
CLINICAL_TRIALS withdrawal · 2017-05-09Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension [Phase 4]
A Phase 4 trial evaluating safety, tolerability, pharmacokinetics and efficacy of two different rates of subcutaneous treprostinil dose titr…
-
FDA label_change · 2017-05-05FDA Approved: ADCIRCA — Supplemental Application (United Therapeutics Corporation)
The FDA highlights a supplemental application for ADCIRCA (tadalafil) submitted by United Therapeutics Corporation, likely related to labeli…
-
CLINICAL_TRIALS trial_result · 2017-05-05Clinical Trial Update: Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension [Phase 3]
Phase 3 clinical trial assessing how long-term oxygen therapy affects exercise capacity and quality of life in patients with pulmonary arter…
-
CLINICAL_TRIALS trial_result · 2017-05-03Clinical Trial Update: Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery
Duke University-sponsored trial evaluating symptomatic pulmonary arterial hypertension after mitral valve surgery has completed.
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude [Phase 4]
A Phase 4 clinical trial evaluating riociguat's effects on exercise performance and pulmonary artery pressure at high altitude; the study wa…
-
CLINICAL_TRIALS withdrawal · 2017-04-11Clinical Trial Update: Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH [Phase 2]
A Phase 2 trial investigating the safety of transitioning from selexipag to Remodulin and then to oral treprostinil in adults with pulmonary…
-
CLINICAL_TRIALS trial_result · 2017-04-06Clinical Trial Update: Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects [Phase 4]
Phase 4 study evaluating a thermostable formulation of FLOLAN (epoprostenol) in Japanese patients with pulmonary arterial hypertension, with…
-
CLINICAL_TRIALS research · 2017-04-06Clinical Trial Update: Impact of Rehabilitation Program on PAH Patients Treated With Macitentan. [NA]
This clinical trial update discusses the effect of a rehabilitation program on patients with pulmonary arterial hypertension who are treated…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension [Phase 4]
Phase 4 trial evaluating safety and efficacy of sildenafil in children with pulmonary arterial hypertension has completed with results poste…
-
CLINICAL_TRIALS trial_result · 2017-03-31Clinical Trial Update: Insulin Resistance in Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 trial investigating insulin resistance in pulmonary arterial hypertension was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Bosentan in Children With Pulmonary Arterial Hypertension Extension Study [Phase 3]
This update covers the completion and results posting of a Phase 3 extension study of bosentan in children with pulmonary arterial hypertens…
-
FDA approval · 2017-03-21FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) submitted by Actelion Pharmaceuticals US, Inc.
-
CLINICAL_TRIALS trial_result · 2017-03-15Clinical Trial Update: Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
A completed clinical trial examined Ventavis (iloprost) inhalation behavior using the I-Neb AAD system in patients with pulmonary arterial h…
-
CLINICAL_TRIALS trial_result · 2017-03-06Clinical Trial Update: Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® [Phase 2]
Phase 2 trial update evaluating UT-15C SR added to Tyvaso in patients with pulmonary arterial hypertension; study completed with posted resu…
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension [Phase 1]
Phase 1 study update on ranolazine for pulmonary arterial hypertension reports completed results for acute and short-term administration.
-
CLINICAL_TRIALS trial_result · 2017-02-24Clinical Trial Update: A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
A clinical trial assessed the safety and efficacy of treprostinil to facilitate liver transplantation in patients with portopulmonary hypert…
-
FDA approval · 2017-02-23FDA Approved: ADEMPAS — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for ADEMPAS (riociguat) from Bayer HealthCare Pharmaceuticals Inc.